16 stories found
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Morningstar
Sarepta Therapeutics, seeking a turnaround, has announced the appointment of former AbbVie executive Severino as its new Chief Executive Officer.
An analysis explores the importance of Elevidys for Sarepta Therapeutics Inc. (SRPT) stock performance and future prospects.
Sarepta Therapeutics (SRPT) shares skyrocketed 35% following a price target hike from Morgan Stanley and the announcement of stellar trial results for the company.
An analysis presents a 'bull case theory' for Sarepta Therapeutics, Inc. (SRPT) stock, suggesting potential for growth.
Sarepta Therapeutics projects a 2026 revenue target of $1.2 billion to $1.4 billion, driven by an intensified educational push for its drug ELEVIDYS.
A summary of Sarepta Therapeutics, Inc.'s second-quarter 2026 earnings call has been released.
Sarepta Therapeutics Inc. (SRPT) is noted as one of the most shorted small-cap stocks to consider buying, with improving profitability supporting its outlook. This indicates a positive financial trend despite high short interest.
Sarepta Therapeutics has reiterated its net product revenue guidance of $1.2 billion to $1.4 billion for 2026, while also aiming to release Cohort 8 data by the end of the year.
Sarepta Therapeutics saw its stock increase following the release of positive data concerning its therapies for muscular dystrophy.
The CEO of Sarepta Therapeutics is reportedly leaving the company following a challenging year.
Sarepta Therapeutics has announced the appointment of Michael Severino as its new Chief Executive Officer.
Sarepta Therapeutics Inc (SRPT) is in a strong cash position and has outlined its strategic priorities and goals for the year 2026.
Sarepta Therapeutics' stock turned negative despite the company reporting better-than-expected first-quarter earnings, while its 2026 guidance remains unchanged.
Wells Fargo has reduced its price target for Sarepta Therapeutics (SRPT) from $45 to $38.
Sarepta Therapeutics CEO Ingram to retire by year end Reuters